Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with localized (non-spreading) breast cancer
- People who are over 18 years old
- People whose medical team has recommended chemotherapy, with or without immunotherapy or targeted therapy, either before or after surgery
- People who have given their signed consent to participate
- People who have national health insurance coverage in France
Who may not be able to join:
- People who have previously received chemotherapy for breast cancer
- People whose breast cancer has spread to other parts of the body (metastatic)
- People who had a psychiatric illness or were taking certain psychiatric medications (such as antidepressants, antipsychotics, or mood stabilisers) before their cancer diagnosis — though people who had a depressive episode that fully resolved, with no psychiatric treatment for at least 2 years, may still be considered (confirm with trial site)
- People currently experiencing active psychiatric conditions such as delusional episodes or schizophrenia that would prevent them from safely taking part in sophrology sessions (a relaxation-based mind-body practice)
- People who have already tried sophrology in connection with their cancer, or who plan to start sophrology on their own outside the hospital within 3 months of beginning treatment
- People who do not speak or understand French
- People who have cognitive difficulties or trouble understanding information that would affect their ability to take part in the study
- People who are under legal protection, guardianship, or trusteeship
- People who are unable to attend follow-up visits due to geographic or social circumstances
- People who are already participating in another interventional study related to supportive care
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Simmet, Institut de Cancérologie de l'Ouest
Phone: +33 2 41 35 27 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To measure the evolution of anxiety in patients undergoing adjuvant or neoadjuvant chemotherapy treatment, depending on whether they benefit from a sophrology program through an ambulatory sophrology device (Morphée®)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.